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Background: Inhaled therapies reduce risk of chronic obstructive pulmonary disease (COPD) exacerbations, but
their effect on mortality is less well established. We hypothesized that heterogeneity in baseline mortality risk
influenced the results of drug trials assessing mortality in COPD.
Methods: The 5706 patients with COPD from the Understanding Potential Long-term Impacts on Function with
Tiotropium (UPLIFT®) study that had complete clinical information for variables associated with mortality (age,
forced expiratory volume in 1 s, St George’s Respiratory Questionnaire, pack-years and body mass index) were
classified by cluster analysis. Baseline risk of mortality between clusters, and impact of tiotropium were evaluated
during the 4-yr follow up.
Results: Four clusters were identified, including low-risk (low mortality rate) patients (n = 2339; 41%; cluster 2), and
high-risk patients (n = 1022; 18%; cluster 3), who had a 2.6- and a six-fold increase in all-cause and respiratory
mortality compared with cluster 2, respectively. Tiotropium reduced exacerbations in all clusters, and reduced
hospitalizations in high-risk patients (p < 0.05). The beneficial effect of tiotropium on all-cause mortality in the
overall population (hazard ratio, 0.87; 95% confidence interval, 0.75–1.00, p = 0.054) was explained by a 21%
reduction in cluster 3 (p = 0.07), with no effect in other clusters.
Conclusions: Large variations in baseline risks of mortality existed among patients in the UPLIFT® study. Inclusion
of numerous low-risk patients may have reduced the ability to show beneficial effect on mortality. Future clinical
trials should consider selective inclusion of high-risk patients.
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Chronic obstructive pulmonary disease (COPD) is a
major health problem associated with disability, health-
care utilization, and premature death [1]. Clinical trials
have established that current pharmacologic approaches
can improve lung function and reduce exacerbations,
but their efficacy in modifying the disease course is a
subject of debate [2]. In recent years, large long-term
clinical trials evaluated pharmacologic intervention on
mortality rates (as primary or secondary outcomes) in
patients with COPD [3,4]. Although these studies have
suggested that current inhaled therapies have some* Correspondence: pierre-regis.burgel@cch.aphp.fr
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unless otherwise stated.effects on mortality [3,5], no study has shown unequivo-
cally that current pharmacotherapy reduced mortality
in patients with COPD [6].
One possible explanation for the limited effect seen in
long-term clinical trials on mortality [3,5] could be an
actually limited efficacy of current drugs on this out-
come. Alternatively, these results may have been related
to the design of clinical trials that assessed mortality in
patients with COPD, and the heterogeneity of baseline
mortality risk among those patients recruited in these
clinical trials may have played an important role: it is
well established that most trial outcomes (e.g. mortality)
occur in a relatively small number of high-risk patients,
while most patients are at much lower risk [7,8]. A clin-
ical trial enrolling a large group of patients with COPD
at low risk of outcome may find the therapy uselessLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tients [7]. These considerations suggest the importance
of risk stratification in clinical trials [7]. However, strati-
fication of mortality risks was not performed in the re-
cent Towards a Revolution in COPD Health (TORCH)
[3] and Understanding Potential Long-term Impacts on
Function with Tiotropium (UPLIFT®) [4] clinical trials,
which may have limited their ability to detect important
differences in mortality.
In the present study, we explored the possibility that the
population recruited in the UPLIFT® study, a 4-year trial
of tiotropium use in patients with COPD, was composed
of patients with large variations in baseline mortality risk.
Our strategy was to examine mortality risk heterogeneity
using a cluster analysis of variables selected for their previ-
ously reported association with increased mortality, and
obtained at recruitment in the study. Our goals were to
identify clusters of patients with different mortality risks at
baseline and to examine the impact of risk stratification
on the evaluation of tiotropium effect on mortality, as well
as to an outcome associated with increased mortality, e.g.
exacerbations. Some of the results of these studies have
been previously reported in abstract form [9].
Methods
Patients and study design
UPLIFT® was a 4-year, randomized, placebo-controlled,
clinical trial in 5993 patients with COPD. Details of the
study design and results have been previously reported
[4,10]. All patients gave written informed consent and the
study was approved by a local Institutional Review Board
(IRB) or an Independent Ethics Committee (IEC) at each
center prior to the start of the study. The constitution of
the IRB or IEC met the requirements of each of the 37 par-
ticipating countries. Criteria for participation included diag-
nosis of COPD, aged at least 40 years, smoking history of
at least 10 pack-years, and post-bronchodilator forcedFigure 1 Dendrogram showing progressive joining of the clustering p
Characteristics of subjects in each cluster are presented in Table 1. The vertexpiratory volume in 1 s (FEV1) ≤ 70% of the predicted nor-
mal, and FEV1 ≤ 70% of forced vital capacity (FVC). Post-
randomization clinic visits occurred at 1 and 3 months, and
then every 3 months throughout the 4-year treatment
period. Eligible patients were randomized to receive either
tiotropium 18 μg or a matching placebo, once daily, deliv-
ered via the HandiHaler® device (Boehringer Ingelheim
Pharma GmbH & Co KG, Ingelheim, Germany).
The primary endpoints were yearly rate of decline in
pre- and post-bronchodilator lung function until comple-
tion of the double-blind treatment. Secondary outcomes
included other lung function measures, health-related
quality of life (HRQoL) as measured by the St George’s
Respiratory Questionnaire (SGRQ) total score, COPD ex-
acerbations and related hospitalizations (severe exacerba-
tions), and mortality. Exacerbations were defined as an
increase in, or new onset of, more than one respiratory
symptom with duration of 3 or more days and requiring
treatment with an antibiotic and/or systemic steroid. Data
from COPD exacerbations and related hospitalizations were
collected on study-specific case report forms at every visit.
Detailed description of mortality data collection was previ-
ously described [5]. Mortality was described at Day 1440
(protocol-defined end of 4-year treatment period) and spe-
cific causes of mortality were determined by an independ-
ent mortality adjudication committee [11]. Comorbidities
were assessed based on patient’s files and self-reports.
Statistics
General statistics
Data are reported as median (interquartile range) or per-
centage, unless otherwise specified. Statistical significance
was considered at p < 0.05. For time to first exacerbation,
time to first hospitalization, and time to all-cause and re-
spiratory death, survival probability was estimated using
Kaplan-Meier analysis. Cox regression with cluster was
used in the control group to test cluster effect. Hazard ratiorocess. Data can be optimally grouped into four clusters.
ical line identifies the optimal number of clusters in the data.
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timated using Cox regression with treatment, cluster, and
treatment by cluster interaction as factors. Number of exac-
erbations and related hospitalizations were analyzed using a
Poisson regression with over-dispersion adjusted for treat-
ment exposure. All analyses were performed using SAS 9.2
statistical software (SAS Institute Inc, Cary, NC, USA).
Cluster analysis
The following clinical variables obtained at enrolment
in the study were used in the cluster analysis: age [12],
body mass index (BMI) [13], post-bronchodilator FEV1
(percent predicted) [13], smoking (pack-years) [14,15],Table 1 Baseline characteristics of 5706 patients with COPD i
Cluster 1
n = 820
Variables used in the cluster analysis
Age (yrs) 66 (61–71)
BMI (kg/m2) 27 (24–30)
Smoking history (pack-years) 92 (80–110)
Post-bronchodilator FEV1 (% predicted) 49 (41–58)
SGRQ total score 40 (31–52)
Other variables
Gender, M/F (%) 86/14
Current smokers (%) 28
Post-bronchodilator FEV1/FVC (%) 43 (36–51)
COPD duration (yrs) 8 (4–13)
Spirometric GOLD stage, n (% cluster) (% GOLD stage)
GOLD stage 1 0
GOLD stage 2 408 (50%) (16%
GOLD stage 3 372 (45%) (14%
GOLD stage 4 40 (5%) (8%)
Baseline medications (%)
LABA 54
ICS 54
ICS + LABA 43
Anticholinergic* 48
Comorbidities (%)
Coronary artery disease 19
Left heart failure 4
Hypertension 47
Diabetes 13
Randomization group
Tiotropium/control (n) 410/410
*Short-acting.
BMI = Body mass index, COPD = Chronic obstructive pulmonary disease, FEV1 = Force
for Chronic Obstructive Lung Disease, ICS = Inhaled corticosteroid, LABA = Long-acting
Potential Long-term Impacts on Function with Tiotropium.and SGRQ total score [16]. This selection of variables
was based on their previously reported association with
mortality in patients with COPD, and their availability
in the UPLIFT® study.
All patients with complete data for these five variables
were classified using a Ward’s cluster analysis in which
grouping was based on quantitative measures of similarity
procedure (minimum within cluster sum of square).
Pseudo-F and pseudo-t2 statistics were used to determine
the optimal number of clusters in the data [17]. Relatively
large pseudo F values were considered to indicate a stop-
ping point. For the pseudo t2 statistic, we moved down
the column until we found the first value markedly largern the UPLIFT® trial by clusters
Cluster 2 Cluster 3 Cluster 4
n = 2339 n = 1022 n = 1525
67 (60–72) 63 (58–70) 63 (56–70)
25 (23–28) 25 (22–29) 25 (22–29)
40 (30–50) 60 (47–70) 30 (20–35)
55 (47–62) 36 (29–46) 43 (36–51)
34 (26–43) 60 (51–70) 55 (47–64)
75/25 76/23 65/35
29 34 29
46 (40–54) 36 (30–45) 40 (34–48)
8 (4–13) 8 (5–14) 9 (5–14)
3 (0.1%) 0 0
) 1,616 (69%) (61%) 192 (19%) (7%) 432 (28%) (16%)
) 685 (29%) (27%) 561 (55%) (22%) 941 (62%) (36%)
35 (2%) (7%) 269 (26%) (54%) 152 (10%) (31%)
57 62 65
60 65 66
47 51 54
40 55 50
6 15 10
2 4 2
16 38 25
5 10 7
1176/1163 517/505 741/784
d expiratory volume in 1 s, FVC = Forced vital capacity, GOLD = Global Initiative
β2-agonist, SGRQ= St George’s Respiratory Questionnaire; UPLIFT® = Understanding
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by one cluster. Clinical endpoints were analyzed for each
cluster to evaluate the relevance of the clustering.
Results
Baseline characteristics and patient classification
The present analysis is based on 5706 patients with COPD
(95.2% of the randomized population) with complete data
for age, BMI, post-bronchodilator FEV1 (percent predicted),
SGRQ total score, and cumulative smoking (pack-years).
Classification of these patients using cluster analysis re-
sulted in a dendrogram that showed the progressive joining
of the clustering process (Figure 1); patients could be opti-
mally classified in four clusters (see Methods section).
Characteristics of patients within these four clusters are
presented in Table 1. Cluster 1 (n = 820 patients [14%])
contained Global Initiative for Chronic Obstructive Lung
Disease (GOLD) Stage 2 or 3 patients, who were heavy
smokers and had relatively preserved HRQoL, but high
rates of comorbidities. Cluster 2 (n = 2339 patients [41%])
contained mostly GOLD Stage 2 patients with moderate
HRQoL impairment and very low rates of comorbidities.
Cluster 3 (n = 1022 patients [18%]) contained 81% of
GOLD Stage 3 and 4 patients, with severe HRQoL impair-
ment, high pack-years, and high rates of comorbidities.
Compared with cluster 3, cluster 4 (n = 1525 [27%]) con-
tained patients with less severe airflow limitation, slightly
less severe HRQoL impairment, and fewer pack-years
and comorbidities. Numbers of patients in the control
versus tiotropium group were rather similar within each
cluster (Table 1) and comparison of the main clinical
characteristics of control versus tiotropium patientsTable 2 Exacerbations, severe exacerbations (hospitalization)
by cluster
Cluster 1
n = 410
Exacerbations
Exacerbations, per patient-year (no.)
Total 0.81 ± 0.05
Leading to hospitalization 0.12 ± 0.02
Time to first exacerbation (months*)
Total 11.9 (10.1, 14.9)
Leading to hospitalization 38.0 (29.9, 49.5)
Patients with exacerbation (n, %)
Total 279 (68.0)
Leading to hospitalization 96 (23.4)
Mortality
All cause, (n, %) 64 (15.6)
Respiratory, (n, %) 24 (5.9)
Data are mean SD or n (%); *First quartile, 95% CI.
CI = Confidence interval, N/A = not estimable, SD = Standard deviation.within each cluster showed no significant difference
(not shown).Heterogeneity in baseline risks of mortality and
exacerbations by clusters in the control group
To gain knowledge on the baseline risk of mortality and
exacerbations in each cluster without interference of an
intervention (tiotropium), we examined these outcomes
over the 4 years of the study in patients randomized in the
control group (n = 2862 patients) according to clusters.
The total number of deaths in the control group was
463 (16.1%). All-cause mortality rates were markedly dif-
ferent among clusters ranging from 11.1% in cluster 2 to
26.1% in cluster 3 (Table 2). Deaths related to respiratory
causes occurred in 158 (5.5%) patients. Respiratory mortal-
ity was very low in cluster 2 (2.1%) and very high in cluster
3 (12.7%). Kaplan-Meier analyses of all-cause mortality and
respiratory mortality by cluster are presented in Figure 2.
Cox regression showed significant difference among clus-
ters (p < 0.0001).
Risk of exacerbations and severe exacerbations were
markedly different among clusters. Patients in cluster 3
had the highest rates of exacerbations (1.21 ± 0.06 per pa-
tient/year) and hospitalizations (0.33 ± 0.03 per patient/
year), whereas patients in cluster 2 had the lowest rates of
exacerbations (0.69 ± 0.03 per patient/year) and hospitali-
zations (0.11 ± 0.01 per patient/year). Kaplan-Meier ana-
lyses of time to first exacerbation and to first severe
exacerbation by cluster in the control group are presented
in Figure 3. Cox regression showed significant difference
among clusters (p < 0.0001)., and mortality rates in the control group (N = 2862)
Cluster 2 Cluster 3 Cluster 4
n = 1163 n = 505 n = 784
0.69 ± 0.03 1.21 ± 0.06 0.91 ± 0.04
0.11 ± 0.01 0.33 ± 0.03 0.17 ± 0.02
17.3 (14.9, 20.0) 7.8 (6.6, 8.9) 11.2 (9.7, 13.9)
43.8 (35.8, N/A) 14.6 (11.9, 17.3) 27.1 (22.8, 31.2)
752 (64.7) 370 (73.3) 543 (69.3)
255 (21.9) 196 (38.8) 219 (27.9)
129 (11.1) 132 (26.1) 138 (17.6)
27 (2.3) 64 (12.7) 43 (5.5)
Figure 2 Kaplan-Meier plots of mortality. All-cause (A) and respiratory (B) mortality by cluster in the control group (n = 2862 patients) are shown.
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severe exacerbations, all-cause and respiratory mortality
by clusters in the control group are shown in Figure 4.
Effect of tiotropium on exacerbations and mortality
by clusters
Because the clusters were defined by baseline factors, and
baseline characteristics were comparable between treat-
ment groups within each cluster, it is possible to compare
treatment groups by cluster. Tiotropium significantly re-
duced exacerbations rates (Figure 5) and also increased
time to first exacerbation in each cluster (not shown). Rates
of severe exacerbations (leading to hospitalization) weresignificantly reduced in cluster 3 (p < 0.05), which had the
highest rate of exacerbations leading to hospitalization, but
not in other clusters.
When considering all patients (n = 5706), all-cause mor-
tality was almost significantly reduced in the tiotropium
versus the control group (hazard ratio [HR], 0.87; 95%
confidence interval [CI], 0.75–1.00; p = 0.054). The effect
was possibly driven by a clear tendency of tiotropium to
reduce mortality in cluster 3 (HR, 0.79; 95% CI, 0.62–1.02;
p = 0.07); whereas, in other clusters, the numerical reduc-
tion of mortality risk in tiotropium was mild (HR, 0.89–
0.92) and not statistically significant (p > 0.35). Similarly, a
trend towards reduction in respiratory mortality was
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Figure 3 Kaplan-Meier plots of exacerbations. Time to first exacerbation (A) and severe exacerbation (B) by cluster in the control group
(n = 2862 patients) are shown.
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0.13), but not in other clusters. The effect of tiotropium
on all-cause and respiratory mortality by cluster is pre-
sented in Figure 5.
Discussion
In the present study, we reasoned that classification of pa-
tients with COPD using a cluster analysis of multiple clin-
ical variables previously associated with increased mortality
may identify clusters of patients with variations in baseline
risks of mortality. We found that risks and causes of mor-
tality were markedly different among patients included inthe UPLIFT® study. Cluster 2, which accounted for 41% of
all patients, contained patients at low risk of mortality and
very low risk of respiratory mortality; these patients were
also at low risk of exacerbations and severe exacerbations.
Compared with this low-risk cluster, risks of all-cause and
respiratory mortality were 2.6- and six-fold higher in clus-
ter 3, respectively, and were also increased in clusters 1
and 4, although to a lesser extent. Tiotropium reduced ex-
acerbations in all clusters, and in particular reduced severe
exacerbations in high-risk patients (cluster 3). Tiotropium
was further suggested to reduce all-cause and respiratory
mortality in high-risk patients (cluster 3), but not in other
Figure 4 Comparison of baseline risks of first exacerbation and first severe exacerbation (A), all-cause and respiratory mortality. (B) by
clusters in the control group (n = 2862 patients) are shown. CI = confidence interval, HR = hazard ratio.
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baseline risk stratification on the interpretation of the re-
sults of large clinical trials in patients with COPD.
The present analysis revealed that more than 40% of
patients (cluster 2) included in this study had low risk of
all-cause mortality and very low risk of respiratory mor-
tality at the time of inclusion in the study. Patients in
clusters 1 and 4 (who also represented more than 40% of
all patients included) had higher baseline risk for all-
cause mortality, but were also at low risk of respiratory
mortality. Thus, more than 80% of patients included in
the UPLIFT® study were at low baseline risk of respira-
tory mortality, which is in line with the risk of dying in
the general population of those with COPD. When gen-
erating the hypothesis that tiotropium could reduce
respiratory mortality, a reasonable hypothesis given its
effect on FEV1 and exacerbations [4], the inclusion of
this large number of low-risk patients may have resulted
in missing the potential benefit of tiotropium in high-
risk patients [7,8]. In support of this latter hypothesis,
our analysis strongly suggested that tiotropium had a ra-
ther large impact on all-cause and respiratory mortalityin high-risk patients (cluster 3), although the analysis
was likely under-powered to show statistical significance.
To the best of our knowledge, no other study has eval-
uated the impact of heterogeneity in baseline risks and
causes of mortality on the results of pharmacologic clin-
ical trials in patients with COPD. In the past, analyses of
potential efficacy of pharmacotherapy on mortality in
patients with COPD have relied on conventional (and most
often post-hoc) subgroup analyses of individual variables to
examine variability in treatment effects among subgroups
[3,5]. However, conventional subgroup analyses are inad-
equate to detect large and clinically important differences
in treatment effect among patients when multiple factors
determine risk [8]. This is typically the case for mortality
risk in patients with COPD, which is determined by mul-
tiple factors including the level of FEV1 impairment, age,
patient-centered outcomes (e.g. dyspnea, HRQoL), and co-
morbidities (e.g. malnutrition) [12,13]. For example, al-
though cluster 3 contained 81% of GOLD Stage 3 and 4
patients (representing 54% and 22% of all GOLD Stage
3 and 4 patients, respectively), GOLD stage per se was
not a significant covariate in the effect of tiotropium on
Figure 5 Impact of tiotropium on the risk of exacerbations and severe exacerbations (A), all-cause and respiratory mortality. (B) by
clusters (n = 5706 patients) are shown. CI = confidence interval, HR = hazard ratio, pts = patients.
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the UPLIFT® study [5]. These data suggest that multi-
dimensional assessment of baseline mortality risk is
more appropriate to provide stratification of mortality
risk in patients with COPD.
Our data strongly suggest that such stratification of clin-
ical trials on baseline mortality risk is of utmost importance
in studies assessing specifically mortality. Prognostic enrich-
ment strategies, aimed at including subjects at high risk of
mortality, may be especially useful in such studies [18]: be-
cause the appropriate sample size necessary to show a re-
duction in mortality rates will depend on effect size and the
event rate in the placebo group, selecting a population at
high risk of mortality would increase the likelihood of show-
ing an effect of a drug, if there is one [18]. Prognostic en-
richment may not increase the relative risk reduction (e.g.
percent improvement in mortality), but will increase theabsolute event counts, allowing for a smaller sample size
[18]. Another advantage of this strategy will be to allow re-
duction in the duration of the study, presumably lowering
study drop-off rates, a common problem in long-term clin-
ical trials, and reducing the cost of the study.
In future studies, prognostic enrichment may rely on val-
idated multivariate risk indices collected at study entry
[12,13]. The BODE index, which is a predictor of all-cause
and of respiratory mortality [13], may be particularly suited
for selecting high-risk patients (and excluding low-risk pa-
tients) in clinical trials assessing the effect of therapy on
mortality in patients with COPD. However, the BODE
index requires a 6-minute walk test, which may be difficult
to use in the screening of patients for large-scale multicen-
ter studies. Alternative strategies for recruiting patients at
high risk of mortality may eventually be considered. Based
on the characteristics of high-risk subjects (cluster 3) in
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airflow limitation and impaired HRQoL (as measured
by a high SGRQ total score) would be candidates for re-
cruitment in these studies. Another possibility would be
to recruit subjects who had experienced at least one
hospitalization for COPD in recent years, as several stud-
ies have shown that 3-year mortality rates in these patients
is approximately 50% [19,20]. Although the most effective
enrichment strategy remains to be established, we suggest
that future clinical trials assessing treatments aimed at re-
ducing mortality in patients with COPD should include
patients at high risk of mortality.
The present analysis was performed on patients with
complete data for five variables, which were previously re-
ported to predict mortality in patients with COPD and
available in the UPLIFT® study. The UPLIFT® study was
performed in 5993 patients, but 287 (4.8%) patients had
missing data for these variables, leading to their exclusion
from the analysis. Because these data were missing at ran-
dom (not shown), as it is often the case in large clinical tri-
als, this is unlikely to affect our conclusions significantly.
Important predictors of mortality (e.g. dyspnea [13] and a
history of severe exacerbations [21]) were not available for
inclusion in the cluster analysis at study entry. Further,
limited clinical data were available to characterize differ-
ences fully among the identified clusters. However, our
analysis was validated by showing that these four clusters
had marked heterogeneity in future outcomes, including
exacerbations, hospitalizations, and all-cause and respira-
tory mortality. In the present study, risk of exacerbations
was also heterogeneous among clusters, but tiotropium re-
duced exacerbations in all clusters of patients, confirming
its positive impact on this outcome [4]. Consequences of
the absence of risk stratification on the results of the UP-
LIFT® study were less important for exacerbations than for
mortality. First, mortality was a relatively rare outcome that
occurred in approximately 15% of patients, whereas exacer-
bations occurred in more than two thirds of patients over
4 years. Second, increases in all-cause and respiratory mor-
tality risks in the highest- versus lowest-risk clusters (up to
2.6- and six-fold, respectively) were more important com-
pared with those in exacerbation risks (fewer than two-
fold). However, the impact of risk heterogeneity was also
important for severe exacerbations leading to hospitaliza-
tions (a relatively rare event with substantial heterogeneity
in risk), and tiotropium significantly reduced hospitaliza-
tions only in high-risk patients (cluster 3).
Conclusion
These data suggest that appropriate patient selection is
a critical component of clinical trial design to ensure
that a sufficient number of patients that are at-risk of
experiencing the outcome(s) of interest (e.g. death) are
recruited in the study.Abbreviations
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